Aurobindo gets 3rd USFDA nod for Hyd unit

Aurobindo Pharma has received USFDA approval for its sterile drug formulation facility near Hyderabad.

This is the third successive USFDA approval for unit-6 (the other approvals being for the formulation orals manufacturing facility and the sterile - API manufacturing facility) at Chitkul near Hyderabad.

The Chitkul unit received the Establishment Inspection Report (EIR) from the USFDA stating their acceptance on the company's sterile injectable formulation facility.